search
Back to results

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

Primary Purpose

Bipolar Disorder

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Lithium
Sponsored by
Indiana University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Bipolar Disorder focused on measuring Major Depressive or Manic Episodes, Bipolar, Mania, Depression, Lithium, fMRI, Pictures, Brain Scan

Eligibility Criteria

15 Years - 60 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for BD participants:

  • Meets DSM-IV criteria for bipolar I or II disorder
  • Meets criteria to undergo an MRI scan based on MRI screening questionnaire
  • Suited for outpatient care during the study as ascertained by a score of less than 5 on the Clinical Global Severity Scale, no significant suicidal or homicidal ideation, and no severe disability

Inclusion criteria for BD depressed participants:

  • Meets criteria for DSM-IV depressive episode-current
  • Score of greater than 15 but less than 30 on the 17-item HDRS
  • Score of less than 12 on the Young Mania Rating Scale

Inclusion criteria for BD (hypo) manic participants:

  • Meets criteria for DSM-IV manic episode-current
  • Score of less than or equal to 18 on the 17-item HDRS
  • Score of greater than 12 but less than 25 on the Young Mania Rating Scale

Inclusion criteria for BD euthymic patients:

  • Satisfy criteria for DSM-IV for euthymic state-current for at least 2 weeks.
  • 17-item Hamilton Depression Rating Scale < 12; Young Mania Rating Scale score < 10

Exclusion criteria for BD participants:

  • Meets DSM-IV criteria for unipolar depression, schizophrenia, schizophreniform disorder, schizoaffective disorder, atypical psychosis, anxiety disorder as a primary diagnosis, mental retardation, or personality disorder
  • Received electroconvulsive therapy in the 12 months prior to study entry
  • Use of neuroleptics, mood stabilizers, or benzodiazepines in the 2 weeks prior to study entry
  • Use of antidepressants in the 2 weeks prior to study entry
  • Use of fluoxetine in the 5 weeks prior to study entry
  • Use of lithium in the 6 months prior to study entry
  • Acutely suicidal or homicidal or requiring inpatient treatment
  • Meets DSM-IV criteria for substance/alcohol dependence, excluding caffeine or nicotine, in the 6 months prior to study entry or substance/alcohol abuse in the 3 months prior to study entry
  • Use of alcohol in the 1 week prior to study entry and refusal to avoid alcohol use during the course of the study
  • Presence of serious acute or chronic medical or neurological illness, including previously known HIV positive status (due to possible CNS involvement) as assessed by history, physical examination, and laboratory examination
  • Pregnant or breastfeeding
  • Metallic implants or other contraindication to MRI

Inclusion criteria for first degree relatives of bipolar disorder subjects:

  • Ages 15-60 years (inclusive) and able to give voluntary informed consent.
  • Have never satisfied criteria for DSM-IV BD.
  • Satisfy criteria to undergo an MRI scan based on MRI screening questionnaire.
  • 17-item Hamilton Depression Rating Scale < 10; Young Mania Rating Scale score < 10

Exclusion criteria for first degree relatives of bipolar disorder subjects:

  • Under 15 years of age.
  • Meeting DSM-IV criteria for current episode of unipolar depression
  • Pregnant or breast feeding.
  • Metallic implants or other contraindication to MRI.
  • Currently taking any prescription or centrally acting medications.
  • Serious acute or chronic medical or neurological illness as assessed by history, physical examination and laboratory examination including CBC and blood chemistry.
  • Use of alcohol in the past 1 week and not being able to avoid alcohol use during the course of the study.

Inclusion criteria for healthy subjects:

  • Ages 18-60 years (inclusive) and able to give voluntary informed consent.
  • No current or past history of psychiatric illness or substance abuse or dependence.
  • No current or past history of psychiatric illness or substance abuse or dependence in a first degree relative.

Exclusion criteria for healthy participants:

  • Under 18 years of age
  • Pregnant or breastfeeding
  • Metallic implants or other contraindication to MRI
  • Significant family history of psychiatric or neurological illness
  • Currently taking any prescription or centrally acting medications
  • Serious acute or chronic medical or neurological illness as assessed by history, physical examination, and laboratory examination
  • Use of alcohol in the 1 week prior to study entry and refusal to avoid alcohol use during the course of the study

Sites / Locations

  • Indiana University Psychiatric Clinic

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Bipolar Manic Subjects Treated

Bipolar Depressed Subjects Treated

Bipolar Euthymic Subjects Treated

Arm Description

Bipolar mania picture response during fMRI before and after treatment with lithium

Bipolar depression picture response during fMRI before and after treatment with lithium

Bipolar euthymia picture response before and after treatment with lithium

Outcomes

Primary Outcome Measures

17-item Hamilton Depression Rating Scale (HDRS)
17-item HDRS is gold standard for measurement of depression with a range from 0 - 52. 10 - 14: mild depression; 14-20 moderate depression; >20: severe and very severe depression.

Secondary Outcome Measures

Young Mania Rating Scale
Gold standard scale to measure mania, Range 0 - 60; 12 - 15 mild mania; 15 - 20 moderate mania; >20 severe mania

Full Information

First Posted
January 8, 2008
Last Updated
August 23, 2016
Sponsor
Indiana University
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00596622
Brief Title
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
Official Title
Dysfunctional Cortico-Limbic Activity and Connectivity in Bipolar Disorder Before and After Lithium Treatment: An fMRI Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Indiana University
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will assess the effects of bipolar disorder on brain activity and will determine if medication changes the brain activity in people with bipolar disorder.
Detailed Description
Bipolar disorder (BD) is a chronic brain disorder that causes dramatic changes in a person's mood and energy. People with BD undergo periods of extreme happiness and extreme sadness, known as episodes of mania and depression. A person undergoing an episode of mania often experiences euphoric moods, increased energy, and aggressive behaviors, while a person in a depressed state often experiences low moods, lack of energy, and feelings of sadness. Researchers have recently discovered that abnormalities in certain brain areas that control emotion are often present in those with BD. It is believed that the severe mood shifts in BD may cause alterations in normal brain activity, specifically in corticolimbic activation and connectivity. Current mood stabilizing medications used to treat people with BD may help normalize these brain activity abnormalities. This study will assess the effects of BD on brain activity using functional magnetic resonance imaging (fMRI) and will determine if treatment with lithium changes the brain activity in people with BD. This 9-week study will include participants who are healthy, have BD, or are siblings of subject with BD. All potential participants will undergo initial testing, which will include a physical examination, blood tests, and an electrocardiogram (EKG). Participants will also be asked to answer questions about their mental health, drug use, personality, family history, and psychological well-being. Eligible participants will then return on a different day to undergo an MRI scan, taking 4 hours to complete. During the scan, participants will be asked to perform tasks designed to show changes in blood flow in specific brain regions. These tasks will include listening to sounds and looking at various letters, words, and pictures. This will mark the completion of the study for healthy participants, first degree relatives, and those participants with BD who do not wish to receive medication treatment. Following the first MRI scan, participants with BD who wish to undergo medication treatment will begin an 8-week course of lithium. Participants will be asked to come to the clinic at least once a week for medication monitoring visits. During these visits, participants will undergo blood draws and assessments on depression and mania. Participants will return for two repeat MRI scans after Weeks 2 and 8 of lithium treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder
Keywords
Major Depressive or Manic Episodes, Bipolar, Mania, Depression, Lithium, fMRI, Pictures, Brain Scan

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bipolar Manic Subjects Treated
Arm Type
Experimental
Arm Description
Bipolar mania picture response during fMRI before and after treatment with lithium
Arm Title
Bipolar Depressed Subjects Treated
Arm Type
Experimental
Arm Description
Bipolar depression picture response during fMRI before and after treatment with lithium
Arm Title
Bipolar Euthymic Subjects Treated
Arm Type
Experimental
Arm Description
Bipolar euthymia picture response before and after treatment with lithium
Intervention Type
Drug
Intervention Name(s)
Lithium
Intervention Description
Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
Primary Outcome Measure Information:
Title
17-item Hamilton Depression Rating Scale (HDRS)
Description
17-item HDRS is gold standard for measurement of depression with a range from 0 - 52. 10 - 14: mild depression; 14-20 moderate depression; >20: severe and very severe depression.
Time Frame
Measured at Baseline and after 8 weeks of treatment
Secondary Outcome Measure Information:
Title
Young Mania Rating Scale
Description
Gold standard scale to measure mania, Range 0 - 60; 12 - 15 mild mania; 15 - 20 moderate mania; >20 severe mania
Time Frame
Baseline and 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for BD participants: Meets DSM-IV criteria for bipolar I or II disorder Meets criteria to undergo an MRI scan based on MRI screening questionnaire Suited for outpatient care during the study as ascertained by a score of less than 5 on the Clinical Global Severity Scale, no significant suicidal or homicidal ideation, and no severe disability Inclusion criteria for BD depressed participants: Meets criteria for DSM-IV depressive episode-current Score of greater than 15 but less than 30 on the 17-item HDRS Score of less than 12 on the Young Mania Rating Scale Inclusion criteria for BD (hypo) manic participants: Meets criteria for DSM-IV manic episode-current Score of less than or equal to 18 on the 17-item HDRS Score of greater than 12 but less than 25 on the Young Mania Rating Scale Inclusion criteria for BD euthymic patients: Satisfy criteria for DSM-IV for euthymic state-current for at least 2 weeks. 17-item Hamilton Depression Rating Scale < 12; Young Mania Rating Scale score < 10 Exclusion criteria for BD participants: Meets DSM-IV criteria for unipolar depression, schizophrenia, schizophreniform disorder, schizoaffective disorder, atypical psychosis, anxiety disorder as a primary diagnosis, mental retardation, or personality disorder Received electroconvulsive therapy in the 12 months prior to study entry Use of neuroleptics, mood stabilizers, or benzodiazepines in the 2 weeks prior to study entry Use of antidepressants in the 2 weeks prior to study entry Use of fluoxetine in the 5 weeks prior to study entry Use of lithium in the 6 months prior to study entry Acutely suicidal or homicidal or requiring inpatient treatment Meets DSM-IV criteria for substance/alcohol dependence, excluding caffeine or nicotine, in the 6 months prior to study entry or substance/alcohol abuse in the 3 months prior to study entry Use of alcohol in the 1 week prior to study entry and refusal to avoid alcohol use during the course of the study Presence of serious acute or chronic medical or neurological illness, including previously known HIV positive status (due to possible CNS involvement) as assessed by history, physical examination, and laboratory examination Pregnant or breastfeeding Metallic implants or other contraindication to MRI Inclusion criteria for first degree relatives of bipolar disorder subjects: Ages 15-60 years (inclusive) and able to give voluntary informed consent. Have never satisfied criteria for DSM-IV BD. Satisfy criteria to undergo an MRI scan based on MRI screening questionnaire. 17-item Hamilton Depression Rating Scale < 10; Young Mania Rating Scale score < 10 Exclusion criteria for first degree relatives of bipolar disorder subjects: Under 15 years of age. Meeting DSM-IV criteria for current episode of unipolar depression Pregnant or breast feeding. Metallic implants or other contraindication to MRI. Currently taking any prescription or centrally acting medications. Serious acute or chronic medical or neurological illness as assessed by history, physical examination and laboratory examination including CBC and blood chemistry. Use of alcohol in the past 1 week and not being able to avoid alcohol use during the course of the study. Inclusion criteria for healthy subjects: Ages 18-60 years (inclusive) and able to give voluntary informed consent. No current or past history of psychiatric illness or substance abuse or dependence. No current or past history of psychiatric illness or substance abuse or dependence in a first degree relative. Exclusion criteria for healthy participants: Under 18 years of age Pregnant or breastfeeding Metallic implants or other contraindication to MRI Significant family history of psychiatric or neurological illness Currently taking any prescription or centrally acting medications Serious acute or chronic medical or neurological illness as assessed by history, physical examination, and laboratory examination Use of alcohol in the 1 week prior to study entry and refusal to avoid alcohol use during the course of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amit Anand, MD
Organizational Affiliation
Indiana University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University Psychiatric Clinic
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46222
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder

We'll reach out to this number within 24 hrs